1 / 9

Neonatal HSV

Neonatal HSV . Morning Report July 1 st , 2013. EPIDEMIOLOGY & TRANSMISSION. Neonatal infection with HSV occurs in 1 out of every 3,200-10,000 live births Approximately 1500 cases annually in US (incidence is increasing) Can be HSV-1 or HSV-2, HSV-2 associated with poorer outcome

rhona
Download Presentation

Neonatal HSV

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Neonatal HSV Morning Report July 1st, 2013

  2. EPIDEMIOLOGY & TRANSMISSION • Neonatal infection with HSV occurs in 1 out of every 3,200-10,000 live births • Approximately 1500 cases annually in US (incidence is increasing) • Can be HSV-1 or HSV-2, HSV-2 associated with poorer outcome • Transmission • Intrauterine: rare • Perinatal: majority of cases (85%); occurs when HSV infection is present in genital tract at time of delivery; mom’s infection can be asymptomatic • MOST NEONATES WITH HSV ARE BORN TO MOTHERS WITHOUT HISTORY OF HSV INFECTION • Postnatal: 10% of cases; when caretaker with active HSV infection has close contact with newborn (ex: herpes labialis)

  3. CLINICAL MANIFESTATIONS • Skin, Eye, Mouth (SEM) Disease • Makes up 45% of neonatal HSV • Usually presents within first 2 wks of life • Skin: • Coalescing or clustering vesicular lesions with erythematous base • Eye: • May initially be asymptomatic • Excessive watering, conjunctival erythema, periorbital skin vesicles • Mouth: • Localized ulcerative lesions of mouth, palate and tongue

  4. CLINICAL MANIFESTATIONS • CNS Disease (HSV Meningoencephalitis) • Approx 30% of neonatal HSV involves CNS • Occurs from retrograde spread from nasopharynx and olfactory nerves to brain or via hematogenous spread in disseminated disease • Usually presents in 2nd or 3rd week of life • Can occur +/- SEM and +/- Disseminated disease, but 70% have skin vesicles at some point in their course • Seizures, lethargy, irritability, tremors, poor feeding, temperature instability • CSF can be normal early in course; classic: mononuclear pleocytosis, normal or low glucose, mildly elevated protein • RBCs in CSF are NOT significantly associated with HSV • EEG: focal or multifocal periodic epileptiform discharges • CT and MRI of brain: edema, hemorrhage, destructive lesions involving temporal, frontal, parietal or brainstem regions

  5. CLINICAL MANIFESTATIONS • Disseminated Disease • Makes up 25% of neonatal HSV; CNS involved in 75% of cases • Present in 1st week of life • Fever, apnea, irritability, lethargy, respiratory distress, abdominal distention, ascites (rarely present with fever alone) • Diagnosis is OFTEN delayed until 2ndwk of life (awaiting results of bacterial sepsis evaluation) • Progression: hepatitis w/ elevated transaminases, ascites, direct hyperbilirubinemia, neutropenia, thrombocytopenia, DIC, NEC, meningoencephalitis + seizures; eventually leads to respiratory failure and shock • Skin vesicles may appear late in course, 20% will never have them • Acute liver failure • Dx is often made after extensive organ damage has occurred

  6. EVALUATION AND DIAGNOSIS • Suspect Neonatal HSV in all infants < 6 wks WITH: • Vesicles • Sepsis-like illness • CSF pleocytosis • Seizures • Focal neurologic signs • Respiratory distress, apnea or progressive pneumonitis • Thrombocytopenia • Elevated liver transaminases, viral hepatitis or acute liver failure • Conjunctivitis • Early in course, can present with persistent fever and negative bacterial cultures***

  7. EVALUATION AND DIAGNOSIS • Comprehensive lab evaluation (even in infants with SEM) • CBC • LFTs + ammonia (to exclude liver failure) • BMP • HSV DNA PCR of blood • CSF cell count, glucose, protein and HSV DNA PCR • Skin scrapings of vesicles for HSV DFA + culture • Surface cultures of conjunctivae, mouth, nose, rectum (single swab)

  8. TREATMENT • Indications for empiric treatment are not standardized • Clinical features suggestive of HSV (vesicles, seizures, lethargy, thrombocytopenia, coagulopathy, hepatomegaly, ascites, transaminitis) • Unclear situations: CSF pleocytosis in well appearing infant, erythema/crusting at scalp electrode site, fever without localizing signs in infant < 21 days old • Acyclovir • Administer at time neonatal HSV is SUSPECTED • Dose is same for all forms of neonatal HSV • 60mg/kg/d divided q8h • Duration of therapy • SEM: minimum 14 days if CNS and disseminated disease is r/o • CNS or Disseminated: minimum 21 days • Repeat LP near end of therapy for HSV PCR; continue acyclovir until PCR is negative

  9. OUTCOME • HSV infection is lifelong; recurrent disease may occur • Disseminated disease • 1 year mortality: 29%; risk increased with severe hepatitis, acute liver failure, DIC • Mortality > 80% in untreated disease • Acute liver failure can be fatal; liver transplantation has been successful in a few reported cases • CNS disease • 1 year mortality: 4%; risk increased with prematurity, seizures, coma • 30% of survivors will have normal neurologic development • SEM disease • Mortality and developmental delay is rare

More Related